GSK lung cancer treatment gets EU orphan drug status.
GSK on Tuesday said its treatment for small-cell lung cancer (SCLC) had received orphan drug status from the European Medicines Agency.
GSK
28 October 2025 07:29:32
Source: Sharecast
The antibody-drug conjugate is known as GSK’227 and the designation was supported by preliminary clinical data showing durable responses in patients with extensive stage SCLC who were treated with GSK'227 in a phase one clinical trial.
“This ODD recognises the potential of GSK'227 to address a significant unmet need for extensive stage-SCLC, an aggressive type of pulmonary neuroendocrine carcinoma with poor outcomes and limited treatment options. An estimated 250,000 patients globally are diagnosed with SCLC each year and it is responsible for approximately 200,000 deaths annually,” GSK said in a statement.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.